{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"To determine whether every 12 week therapy with zoledronic acid is not inferior to every-4-week therapy for patients with multiple myeloma, as measured by the proportion who experience at least one skeletal related event within 24 months after randomization.","groups":[{"description":"Patients with Breast Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Multiple Myeloma 4 Weeks"},{"description":"Patients with Breast Cancer receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Multiple Myeloma 12 Weeks"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"265 patient completed treatment and were analyzed.","reportingStatus":"POSTED","timeFrame":"from baseline up to 24 months","title":"Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Multiple Myeloma","type":"SECONDARY","unitOfMeasure":"Participants"}